Abstract

Mesenchymal stem cells (MSCs) reside quiescently within a specialised ‘niche’ environment in the bone marrow. However, following appropriate signalling cues, MSCs mobilise and migrate out from the niche, typically toward either sites of injury (a regenerative response) or toward primary tumours (an intrinsic homing response, which promotes MSCs as cellular vectors for therapeutic delivery). To date, very little is known about MSC mobilisation. By adopting a 3D MSC niche model, whereby MSC spheroids are cultured within a type I collagen gel, recent studies have highlighted interleukin-6 (IL-6) as a key cytokine involved in MSC migration. Herein, the ability of IL-6 to induce MSC migration was further investigated, and the key matrix metalloproteinases used to effect cell mobilisation were identified. Briefly, the impact of IL-6 on the MSC migration in a two-dimensional model systems was characterised—both visually using an Ibidi chemotaxis plate array (assessing for directional migration) and then via a standard 2D monolayer experiment, where cultured cells were challenged with IL-6 and extracted media tested using an Abcam Human MMP membrane antibody array. The 2D assay displayed a strong migratory response toward IL-6 and analysis of the membrane arrays data showed significant increases of several key MMPs. Both data sets indicated that IL-6 is important in MSC mobilisation and migration. We also investigated the impact of IL-6 induction on MSCs in 3D spheroid culture, serving as a simplistic model of the bone marrow niche, characterised by fluorescently tagged magnetic nanoparticles and identical membrane antibody arrays. An increase in MMP levels secreted by cells treated with 1 ng/mL IL-6 versus control conditions was noted in addition to migration of cells away from the central spheroid mass.

Highlights

  • Stem-cell-based therapies have the potential of becoming the future of medicine [1], personalised to the patient [2]

  • Sourcing embryonic stem cells poses ethical concerns, and current UK regulations restrict their availability to the first 14 days, so a more plentiful source of stem cells would be necessary for wide-scale uptake of stem cell therapy

  • mesenchymal stem cells (MSCs) derived from the bone marrow niche are multipotent, capable of differentiating into osteoblasts, chondroblasts, and adipoblasts [4]

Read more

Summary

Introduction

Stem-cell-based therapies have the potential of becoming the future of medicine [1], personalised to the patient [2]. Embryonic stem cells (ESCs) have the highest differentiation potential, offering limitless possibilities for tissue replacement. Sourcing embryonic stem cells poses ethical concerns, and current UK regulations restrict their availability to the first 14 days, so a more plentiful source of stem cells would be necessary for wide-scale uptake of stem cell therapy. MSCs derived from the bone marrow niche are multipotent, capable of differentiating into osteoblasts (bone), chondroblasts (cartilage), and adipoblasts (fat) [4].

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call